Close Menu

NEW YORK (GenomeWeb) – Biocept announced today that it has signed an agreement under which its Target Selector liquid biopsy tests and services will be marketed to community-based oncologists and hematologists in the US by Miraca Life Sciences (MLS).

Under the terms of the promotion and marketing deal, Texas-based MLS will promote Target Selector testing to its new and existing clinician clients in certain unnamed sales territories in the US. Biocept will perform the tests at its CLIA lab in San Diego.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.